Company intelligence / Profile preview

Creatv MicroTech, Inc.

Ownership: Private
Development stage: Commercial

Overview

Creatv MicroTech has developed proprietary liquid biopsy technologies enabling early detection of cancer, monitoring of recurrence, assessment of treatment response, and companion diagnostics. Their LifeTracDx test can detect all cancers at any stage using blood samples. The company’s technologies are validated across multiple studies covering a wide spectrum of clinical applications. No direct mention of pivotal trial results or regulatory approvals found.

Therapeutic areas: Oncology
Modalities: Liquid biopsy (blood-based diagnostics)CellSieve microfilters for cell capture and analysisAssays for circulating tumor cells (CTCs) and cancer-associated macrophage-like cells (CAMLs)Spectrofluorometry for rare biomarker detection
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Creatv MicroTech, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Creatv MicroTech, Inc..

Explore the full profile